• PDF / 169,994 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 34 Downloads / 143 Views

DOWNLOAD

REPORT

---

1 S

Thrombocytopenia and palmar-plantar erythrodysesthesia: case report A 50-year-old woman developed thrombocytopenia and palmar-plantar erythrodysesthesia during treatment with lanreotide, capecitabine and temozolomide for stage IV metastatic duodenal grade 1 somatostatinoma [routes, durations of treatments to reactions onsets and outcomes not stated]. The woman, who had diabetes mellitus and vitamin D deficiency presented with diarrhoea, epigastric abdominal pain and 30kg weight loss in the last 2 years. She did not have any other significant personal or family history. Following investigations, she was clinically diagnosed with neurofibromatosis type 1 (NF1). Later, according to the American Joint Committee on Cancer TNM staging system for neuroendocrine tumors and further investigations, a diagnosis of stage IV metastatic duodenal grade 1 somatostatinoma was made. Therefore, she was started on lanreotide [lanreotide Autogel] 120mg every 28 days along with a CAPTEM regimen included capecitabine 750 mg/m2 twice daily on days 1–14 and temozolomide 200 mg/m2 once daily on days 10–14 every 28 days. After the first 2 months of initiation of therapy, her underlying diarrhoea resolved. Subsequently, she was followed-up at 3, 6, 9 and 12 months and thorax CT and abdominal MRI revealed the stable disease. In May 2020, at 16 months from the diagnosis, a repeated CT scan showed liver metastasis of somatostatinoma. She tolerated the lanreotide, capecitabine and temozolomide treatment well except for the development of grade 2 thrombocytopenia at cycles 3 and 4, and grade 2 palmar-plantar erythrodysesthesia at cycles 3, 4 and 5. Martin S, et al. Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature. Diagnostics 10: 1-16, No. 9, Sep 2020. Available from: URL: 803518217 http://doi.org/10.3390/diagnostics10090620

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832